These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 24127546)

  • 1. On the effects of malaria treatment on parasite drug resistance--probability modelling of genotyped malaria infections.
    Kum CK; Thorburn D; Ghilagaber G; Gil P; Björkman A
    Int J Biostat; 2013 Oct; 9(1):. PubMed ID: 24127546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of the 437G mutation associated with sulfadoxine resistance among Plasmodium falciparum clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine.
    Zakeri S; Farahani MS; Afsharpad M; Salehi M; Raeisi A; Djadid ND
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e123-8. PubMed ID: 20399698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
    Eriksen J; Mwankusye S; Mduma S; Kitua A; Swedberg G; Tomson G; Gustafsson LL; Warsame M
    Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):347-53. PubMed ID: 15099990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria.
    Barnes KI; Little F; Mabuza A; Mngomezulu N; Govere J; Durrheim D; Roper C; Watkins B; White NJ
    J Infect Dis; 2008 Jun; 197(11):1605-13. PubMed ID: 18471066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine.
    Marks F; von Kalckreuth V; Kobbe R; Adjei S; Adjei O; Horstmann RD; Meyer CG; May J
    J Infect Dis; 2005 Dec; 192(11):1962-5. PubMed ID: 16267768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria.
    Humphreys GS; Merinopoulos I; Ahmed J; Whitty CJ; Mutabingwa TK; Sutherland CJ; Hallett RL
    Antimicrob Agents Chemother; 2007 Mar; 51(3):991-7. PubMed ID: 17194834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania.
    Eriksen J; Mwankusye S; Mduma S; Veiga MI; Kitua A; Tomson G; Petzold MG; Swedberg G; Gustafsson LL; Warsame M
    Trans R Soc Trop Med Hyg; 2008 Feb; 102(2):137-42. PubMed ID: 18082233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.
    Schönfeld M; Barreto Miranda I; Schunk M; Maduhu I; Maboko L; Hoelscher M; Berens-Riha N; Kitua A; Löscher T
    Malar J; 2007 Jan; 6():2. PubMed ID: 17224049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular monitoring of Plasmodium falciparum resistance to antimalarial drugs after adoption of sulfadoxine-pyrimethamine plus artesunate as the first line treatment in Iran.
    Afsharpad M; Zakeri S; Pirahmadi S; Djadid ND
    Acta Trop; 2012 Jan; 121(1):13-8. PubMed ID: 22001304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi/c) in Senegal.
    Ndiaye M; Tine R; Faye B; Ndiaye JL; Diouf I; Lo AC; Sylla K; Dieng Y; Hallett R; Alifrangis M; Gaye O
    C R Biol; 2013; 336(5-6):295-300. PubMed ID: 23916206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia.
    Al-Farsi HM; Al-Hashami ZS; Bin Dajem SM; Al-Sheikh AA; Al-Qahtani A; Beja-Pereira A; Idris MA; Babiker HA
    Infect Genet Evol; 2012 Aug; 12(6):1253-9. PubMed ID: 22709478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
    Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
    Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
    Happi CT; Gbotosho GO; Folarin OA; Akinboye DO; Yusuf BO; Ebong OO; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
    Acta Trop; 2005 Sep; 95(3):183-93. PubMed ID: 16023986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
    Swarthout TD; van den Broek IV; Kayembe G; Montgomery J; Pota H; Roper C
    Trop Med Int Health; 2006 Oct; 11(10):1503-11. PubMed ID: 17002724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmodium falciparum in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area.
    Omar SA; Adagu IS; Gump DW; Ndaru NP; Warhurst DC
    Ann Trop Med Parasitol; 2001 Oct; 95(7):661-9. PubMed ID: 11784419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced variation around drug-resistant dhfr alleles in African Plasmodium falciparum.
    Pearce R; Malisa A; Kachur SP; Barnes K; Sharp B; Roper C
    Mol Biol Evol; 2005 Sep; 22(9):1834-44. PubMed ID: 15917494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of sulfadoxine/pyrimethamine resistance alleles in Plasmodium falciparum parasites from Bangladesh.
    Marma AS; Mita T; Eto H; Tsukahara T; Sarker S; Endo H
    Parasitol Int; 2010 Jun; 59(2):178-82. PubMed ID: 20097306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct haplotypes of dhfr and dhps among Plasmodium falciparum isolates in an area of high level of sulfadoxine-pyrimethamine (SP) resistance in eastern Sudan.
    Al-Saai S; Kheir A; Abdel-Muhsin AM; Al-Ghazali A; Nwakanma D; Swedberg G; Babiker HA
    Infect Genet Evol; 2009 Sep; 9(5):778-83. PubMed ID: 19379843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria.
    Dorsey G; Vlahos J; Kamya MR; Staedke SG; Rosenthal PJ
    J Infect Dis; 2003 Oct; 188(8):1231-8. PubMed ID: 14551894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
    Tahar R; Basco LK
    Acta Trop; 2007 Aug; 103(2):81-9. PubMed ID: 17640607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.